UCHL1 promotes cancer stemness in triple-negative breast cancer
C Tian, Y Liu, Y Liu, P Hu, S Xie, Y Guo, H Wang… - … -Research and Practice, 2022 - Elsevier
Background Triple-negative breast cancer (TNBC) is a special kind of breast cancer with
strong ability of invasion and metastasis. UCHL1 belongs to the ubiquitin carboxy-terminal …
strong ability of invasion and metastasis. UCHL1 belongs to the ubiquitin carboxy-terminal …
Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma
Even though tamoxifen has significantly improved the survival of estrogen receptor positive
(ER+) mammary carcinoma (MC) patients, the development of drug resistance with …
(ER+) mammary carcinoma (MC) patients, the development of drug resistance with …
JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1
Q Wang, J Wu, H Wei, H Huang, Y Huang… - … International Journal of …, 2021 - Elsevier
Increased stemness is causally linked to development of drug resistance in cancers. JARID2
is a member of the Jumonji family of proteins and regulates differentiation of embryonic stem …
is a member of the Jumonji family of proteins and regulates differentiation of embryonic stem …
SETD8 induces stemness and epithelial–mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression
M Liu, Y Shi, Q Hu, Y Qin, S Ji, W Liu… - Acta Biochimica et …, 2021 - academic.oup.com
Pancreatic cancer (PC) is one of the most deadly diseases, and its incidence is increasing
year by year. The methyltransferase SETD8 has been demonstrated to play an important …
year by year. The methyltransferase SETD8 has been demonstrated to play an important …
Development of Dl1. 72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer
Simple Summary Over 70% of breast cancers (BCs) are estrogen receptor-positive (ER+).
The development of endocrine therapy has considerably improved patient outcomes …
The development of endocrine therapy has considerably improved patient outcomes …
M2 macrophages predicted the prognosis of breast cancer by combing a novel immune cell signature and promoted cell migration and invasion of cancer cells in vitro.
Q Xia, X Chen, Q Ma, X Wen - Biocell, 2024 - search.ebscohost.com
Background: Breast cancer (BC) is the most common cancer and the leading cause of
cancer death in women. Immune features play an important role in improving the prognosis …
cancer death in women. Immune features play an important role in improving the prognosis …
Oct4/Sox2 positive breast cancer stem cell-like cells can be detected and targeted by including AURKA and Vimentin in the combinatorial marker profile
D Sengupta, D Thakur, E Mahapatra, S Das, S Sen… - 2023 - preprints.org
Aurora Kinase A being overexpressed in majority of cancers, appear to be an attractive
therapeutic target. However, a Phase III clinical trial of Alisertib, a selective AURKA inhibitor …
therapeutic target. However, a Phase III clinical trial of Alisertib, a selective AURKA inhibitor …
An Investigation of the Anti-stemness Actions of Two miRnas after Their Induction by Aminoflavone in Luminal a Breast Cancer
NUR Mavingire - 2022 - search.proquest.com
Approximately 40% of estrogen receptor-positive breast cancer (BC) patients develop
resistance to endocrine therapy (ET) agents like tamoxifen (Tam). Resistance promotes …
resistance to endocrine therapy (ET) agents like tamoxifen (Tam). Resistance promotes …
[PDF][PDF] Development of Dl1. 72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer. Cancers 2021, 13, 4074
The Notch-signaling ligand DLL1 has emerged as an important player and promising
therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell …
therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell …